[
  {
    "ts": null,
    "headline": "Jim Cramer Says “I Like AstraZeneca Very Much”",
    "summary": "AstraZeneca PLC (NASDAQ:AZN) is one of the stocks Jim Cramer shed light on recently. When a caller mentioned that they are thinking of selling their position in the stock for profit and buying ABBV shares, Cramer remarked: I like AstraZeneca very much. And that cancer franchise turned out to be a lot stronger than I […]",
    "url": "https://finnhub.io/api/news?id=f054400007b88f52d86377e76ef642926fc3ef26732575e2cdd4e8c17cbac324",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770136447,
      "headline": "Jim Cramer Says “I Like AstraZeneca Very Much”",
      "id": 138344092,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AstraZeneca PLC (NASDAQ:AZN) is one of the stocks Jim Cramer shed light on recently. When a caller mentioned that they are thinking of selling their position in the stock for profit and buying ABBV shares, Cramer remarked: I like AstraZeneca very much. And that cancer franchise turned out to be a lot stronger than I […]",
      "url": "https://finnhub.io/api/news?id=f054400007b88f52d86377e76ef642926fc3ef26732575e2cdd4e8c17cbac324"
    }
  },
  {
    "ts": null,
    "headline": "Silver Economy Boom: Investing in Healthcare's Aging Tailwinds",
    "summary": "An aging population is reshaping healthcare, with BSX, RMD, ABBV and AMGN positioned to benefit from rising senior care demand.",
    "url": "https://finnhub.io/api/news?id=86913971a38664fa1f8c01de5e87a4832c1200b2daafc58749a3c5d3986040d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770135480,
      "headline": "Silver Economy Boom: Investing in Healthcare's Aging Tailwinds",
      "id": 138344914,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "An aging population is reshaping healthcare, with BSX, RMD, ABBV and AMGN positioned to benefit from rising senior care demand.",
      "url": "https://finnhub.io/api/news?id=86913971a38664fa1f8c01de5e87a4832c1200b2daafc58749a3c5d3986040d2"
    }
  },
  {
    "ts": null,
    "headline": "Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program",
    "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of the Faces of Natrelle® Testimonial Program, a nationwide initiative inviting women to share their real stories and experiences with Natrelle® breast implants to help educate, empower, and support others considering breast surgery.",
    "url": "https://finnhub.io/api/news?id=fc37ad4af58033c03ad967bec2a7e0b2776975a2e90db86429e7779391dcde39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770126600,
      "headline": "Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program",
      "id": 138341614,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of the Faces of Natrelle® Testimonial Program, a nationwide initiative inviting women to share their real stories and experiences with Natrelle® breast implants to help educate, empower, and support others considering breast surgery.",
      "url": "https://finnhub.io/api/news?id=fc37ad4af58033c03ad967bec2a7e0b2776975a2e90db86429e7779391dcde39"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Targets Post Humira Growth With Cell Therapy And RINVOQ Expansion",
    "summary": "AbbVie (NYSE:ABBV) has agreed to acquire Capstan Therapeutics to expand its work in in vivo CAR-T cell therapy. The company has also submitted upadacitinib (RINVOQ) for FDA and EMA review as a potential treatment for vitiligo. For you as an investor, these updates relate to AbbVie’s strategy after Humira's patent expiry to position itself as a broad-based biopharma company with exposure to complex immunology and oncology treatments. The Capstan deal adds a new cell therapy platform, while...",
    "url": "https://finnhub.io/api/news?id=a49fb327ac11b89a9ab9317dd734fc7f2c1a9ea2b93b907d848d1846aa663fe7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770124912,
      "headline": "AbbVie Targets Post Humira Growth With Cell Therapy And RINVOQ Expansion",
      "id": 138341615,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE:ABBV) has agreed to acquire Capstan Therapeutics to expand its work in in vivo CAR-T cell therapy. The company has also submitted upadacitinib (RINVOQ) for FDA and EMA review as a potential treatment for vitiligo. For you as an investor, these updates relate to AbbVie’s strategy after Humira's patent expiry to position itself as a broad-based biopharma company with exposure to complex immunology and oncology treatments. The Capstan deal adds a new cell therapy platform, while...",
      "url": "https://finnhub.io/api/news?id=a49fb327ac11b89a9ab9317dd734fc7f2c1a9ea2b93b907d848d1846aa663fe7"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo",
    "summary": "AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ®; 15 mg, once daily) for the treatment of adult and adolescent patients living with non-segmental vitiligo (NSV). The regulatory submissions to the FDA and EMA are supported by previously announced results from the Viti-Up studies evaluating the safety and efficacy of upadacitinib in patients with N",
    "url": "https://finnhub.io/api/news?id=e9e6a11ebd0ba1e59df1f8dfa593dcffcebfd57deec24b5876dc4d14b79875ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770123600,
      "headline": "AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo",
      "id": 138341616,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ®; 15 mg, once daily) for the treatment of adult and adolescent patients living with non-segmental vitiligo (NSV). The regulatory submissions to the FDA and EMA are supported by previously announced results from the Viti-Up studies evaluating the safety and efficacy of upadacitinib in patients with N",
      "url": "https://finnhub.io/api/news?id=e9e6a11ebd0ba1e59df1f8dfa593dcffcebfd57deec24b5876dc4d14b79875ca"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates",
    "summary": "Pfizer (PFE) delivered earnings and revenue surprises of +16.81% and +4.26%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=9d3412cf1f97fcd857701b290538dd982048dcca4a7d2f23d815ed76f8155134",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770123302,
      "headline": "Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates",
      "id": 138342565,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) delivered earnings and revenue surprises of +16.81% and +4.26%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=9d3412cf1f97fcd857701b290538dd982048dcca4a7d2f23d815ed76f8155134"
    }
  },
  {
    "ts": null,
    "headline": "DGRO: This Diversified Dividend Growth Fund Is Getting Pricey",
    "summary": "DGRO: This Diversified Dividend Growth Fund Is Getting Pricey",
    "url": "https://finnhub.io/api/news?id=ad6eb402da4430178f476b94b861881a01e39777047e6df8fc51a87c56492227",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770121287,
      "headline": "DGRO: This Diversified Dividend Growth Fund Is Getting Pricey",
      "id": 138343719,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ad6eb402da4430178f476b94b861881a01e39777047e6df8fc51a87c56492227"
    }
  },
  {
    "ts": null,
    "headline": "What Does Wall Street Think About AbbVie Inc. (ABBV)?",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best long term low volatility stocks to invest in. On January 27, Citi cut the price target on AbbVie Inc. (NYSE:ABBV) to $230 from $235 while maintaining a Neutral rating on the shares. The firm told investors that it adjusted price targets in the biopharma group as part […]",
    "url": "https://finnhub.io/api/news?id=03f5509d9aed6404e4593da2d23a5b4021b567ceb07a3b0ca3990e05e4a8a0cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770111261,
      "headline": "What Does Wall Street Think About AbbVie Inc. (ABBV)?",
      "id": 138340033,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best long term low volatility stocks to invest in. On January 27, Citi cut the price target on AbbVie Inc. (NYSE:ABBV) to $230 from $235 while maintaining a Neutral rating on the shares. The firm told investors that it adjusted price targets in the biopharma group as part […]",
      "url": "https://finnhub.io/api/news?id=03f5509d9aed6404e4593da2d23a5b4021b567ceb07a3b0ca3990e05e4a8a0cb"
    }
  },
  {
    "ts": null,
    "headline": "Big Tech and Pharma Earnings: What to Watch This Week",
    "summary": "Earnings season marches on. Two more Magnificent Seven tech companies—Alphabet and Amazon—will report, following on the heels of disappointing results from Microsoft that helped send software stocks tumbling last week.",
    "url": "https://finnhub.io/api/news?id=9aa613f24a7650ac7b730d72057e5922be4de4b5ab97ebd182e8d85bdb78a6bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770105706,
      "headline": "Big Tech and Pharma Earnings: What to Watch This Week",
      "id": 138340001,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Earnings season marches on. Two more Magnificent Seven tech companies—Alphabet and Amazon—will report, following on the heels of disappointing results from Microsoft that helped send software stocks tumbling last week.",
      "url": "https://finnhub.io/api/news?id=9aa613f24a7650ac7b730d72057e5922be4de4b5ab97ebd182e8d85bdb78a6bc"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Q4 Earnings: What To Expect",
    "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings this Wednesday before market open. Here’s what to expect.",
    "url": "https://finnhub.io/api/news?id=a0f24601f1794b024c5e2922352b93f490803d2b0ad65108624b0b217289c3db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770088671,
      "headline": "AbbVie (ABBV) Q4 Earnings: What To Expect",
      "id": 138338520,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings this Wednesday before market open. Here’s what to expect.",
      "url": "https://finnhub.io/api/news?id=a0f24601f1794b024c5e2922352b93f490803d2b0ad65108624b0b217289c3db"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV): A Bull Case Theory",
    "summary": "We came across a bullish thesis on AbbVie Inc. on Disruptive Analytics ’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $223.01 as of January 30th. ABBV’s trailing and forward P/E were 166.99 and 15.70 respectively according to Yahoo Finance. AbbVie Inc., a research-based biopharmaceutical […]",
    "url": "https://finnhub.io/api/news?id=44077e303e5d371db055401b366b69a44fe51ab8a2fc8ed8c724ce2ebd27003b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770078519,
      "headline": "AbbVie Inc. (ABBV): A Bull Case Theory",
      "id": 138337973,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on AbbVie Inc. on Disruptive Analytics ’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $223.01 as of January 30th. ABBV’s trailing and forward P/E were 166.99 and 15.70 respectively according to Yahoo Finance. AbbVie Inc., a research-based biopharmaceutical […]",
      "url": "https://finnhub.io/api/news?id=44077e303e5d371db055401b366b69a44fe51ab8a2fc8ed8c724ce2ebd27003b"
    }
  }
]